Trump Administration Urges Congress to Preserve CBD Access

Administration Position on Hemp-Derived CBD

The White House is lobbying Capitol Hill to maintain the current statutory exemption for CBD extracted from lawfully cultivated hemp. Officials are reaching out after months of regulatory ambiguity surrounding hemp-derived cannabinoids. The Food and Drug Administration continues to delay finalizing rules for CBD in food and dietary supplements.

According to the greenstate.com report, administration officials have engaged with members of the House and Senate agriculture committees. The conversations focus on preserving language in the 2018 Farm Bill that distinguishes hemp from marijuana based on THC concentration thresholds.

Regulatory Timeline and FDA Inaction

FDA hasn't issued final guidance on CBD products despite a statutory mandate to do so within two years of the 2018 Farm Bill's enactment. That deadline passed in December 2020. The agency published an advance notice of proposed rulemaking in 2023 but hasn't moved forward with formal regulations.

State-level CBD regulations vary widely. Some states have adopted permissive frameworks. Others impose strict labeling and testing requirements. Industry stakeholders estimate the U.S. CBD market at $5 billion annually, though exact figures remain uncertain due to inconsistent reporting standards — a fragmented landscape that the delay has only worsened.

Congressional Context and Farm Bill Reauthorization

The 2023 Farm Bill reauthorization is pending in Congress, with hemp provisions a focal point of negotiations. House Agriculture Committee Chair Glenn Thompson has indicated support for maintaining hemp's legal status but has also called for tighter oversight of intoxicating hemp-derived cannabinoids such as delta-8 THC.

Senate Agriculture Committee ranking member John Boozman has proposed amendments that would grant FDA explicit authority to regulate CBD as a food ingredient. Hemp trade groups oppose that proposal. They argue it would effectively re-schedule CBD by subjecting it to the same approval pathway as pharmaceutical drugs.

Industry Reaction and Market Implications

Hemp industry organizations have welcomed the administration's position but remain cautious about enforcement gaps. The U.S. Hemp Roundtable and the Hemp Industries Association both issued statements praising the White House's engagement with Congress. Both groups emphasized that statutory protection alone isn't sufficient without clear FDA rules.

Market analysts note that the administration's stance may stabilize investor confidence in the CBD sector. Publicly traded hemp companies saw share-price gains on June 9 following the greenstate.com report, though trading volumes remained modest.

Enforcement Priorities and DEA Coordination

The Drug Enforcement Administration hasn't issued new guidance on hemp-derived CBD since the 2018 Farm Bill took effect. DEA's Diversion Control Division continues to treat hemp extracts as exempt from scheduling provided they meet the statutory THC threshold. State-level law enforcement agencies have inconsistently applied that standard, particularly in states without explicit hemp programs.

The administration's congressional outreach may signal an effort to preempt DEA rulemaking that could narrow the hemp exemption. DEA has authority under the Controlled Substances Act to schedule substances by analogue or by chemical structure — a power that could theoretically extend to cannabinoids regardless of their botanical source.

Next Steps and Legislative Outlook

Congress is expected to take up Farm Bill reauthorization in the third quarter of 2026, with hemp provisions likely to be debated on the floor. The administration's position gives political cover to lawmakers who support maintaining CBD access but face pressure from constituencies concerned about intoxicating hemp products.

For full background on this story, see the CannIntel topic hub on CBD legal status. The hub tracks federal and state regulatory developments affecting hemp-derived cannabinoids.

The key variable is whether FDA moves forward with rulemaking before Congress acts. If the agency finalizes CBD regulations that conflict with the 2018 Farm Bill framework, lawmakers will face a choice: defer to FDA expertise or override the agency through statute. The administration's intervention suggests a preference for the latter.